原发性胆汁性胆管炎的免疫学图景:机制与治疗前景
本文综述原发性胆汁性胆管炎(PBC)的免疫发病机制,分析胆管上皮的免疫功能、胆汁酸的免疫调节作用及现有治疗所靶向分泌通路的免疫学证据,并讨论以分泌缺陷为核心的新假说及熊去氧胆酸恢复保护机制的途径。
要点
- PBC是进行性破坏肝内胆管的慢性胆汁淤积性肝病,可致纤维化乃至肝硬化。
- PBC被视为原型自身免疫病,以特异性自身抗体和针对线粒体自身抗原的免疫应答为特征。
- 新假说提出胆管上皮细胞原发性衰竭伴阴离子交换蛋白2下调(继发于miR-506过表达)触发免疫风暴。
核心结论
- 分泌缺陷被认为是PBC发病的罪魁祸首和持续因素,熊去氧胆酸通过促进碳酸氢盐分泌和降低胆汁酸毒性帮助恢复该保护机制。
研究设计与样本
- 综述,旨在提供PBC免疫发病机制的最新证据。
主要发现
- 传统观点认为针对胆管上皮细胞的免疫攻击继发胆道转运体(如阴离子交换蛋白2)衰竭是原发事件。
- 近期假说提出胆管上皮细胞原发性衰竭伴阴离子交换蛋白2下调继发于表观遗传机制(miR-506过表达),进而触发免疫风暴。
- 综述分析胆管上皮的免疫功能、胆汁酸的免疫调节功能以及现有治疗所靶向分泌通路的免疫学作用证据。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by the progressive destruction of intrahepatic bile ducts, leading to fibrosis, and potentially cirrhosis. PBC has been considered a prototypical autoimmune condition, given the presence of specific autoantibodies and the immune response against well-defined mitochondrial autoantigens. Further evidence supports the interaction of immunogenetic and environmental factors in the etiology of PBC. An immunological attack on biliary epithelial cells with secondary failure of biliary transporters, eg, the anion exchange protein 2, is traditionally considered the primum movens. A recent hypothesis proposes a primary failure of biliary epithelial cells with the downregulation of anion exchange protein 2 secondary to epigenetic mechanisms (miR-506 overexpression), which then triggers the immunological storm. This highlights the secretory defect as the culprit and sustaining factor in the pathogenesis of PBC with ursodeoxycholic acid helping to restore this protective mechanism by promoting bicarbonate secretion and reducing bile acid toxicity. In this review, we aim to provide the most recent evidence on the immunopathogenesis of PBC. We will analyze the immune function of the biliary epithelium, assessing the immunomodulatory functions of the bile acids and the evidence of the immunological roles of the secretory pathways targeted by the current treatments.
引用
- Ronca V, Davies SP, Oo YH, et al. The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects. Hepatology. 2025. PMID: 39774114. doi:10.1097/HEP.0000000000001225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。